Traded Oct 5 · filed 1 day later
Derivative exercise or conversion — not an open-market buy.
Loading…
Traded Oct 5, 2026 · Filed Oct 6, 2026
The CEO of Repligen sold $238K of Repligen shares. The filing says it was made under a pre-arranged trading plan.
Written from the filing's own figures. OQRO describes what was reported and never tells you what to buy or sell
open market sale
Code S — open-market or private sale
~$238,274
Shares × reported transaction price
69 days after results of Jul 28, 2026
Results dates are the company's own 8-K (Item 2.02). Many companies only let insiders trade in a window after results
Closed at $189.50 on Oct 5, 2026, within 3% of its 52-week high, after a 5% rise over the previous 30 trading days
52-week range $102.87 (May 15, 2026) to $194.57 (Sep 29, 2026), 94% of the way up, from 251 adjusted closes. 30 trading days earlier: $181.13 on Aug 21, 2026. Describes the past only, not a forecast
Footnote references a pre-arranged trading plan (Rule 10b5-1)
Only flagged when a footnote says so; never inferred
Traded Oct 5 · filed 1 day later
Derivative exercise or conversion — not an open-market buy.
Olivier Loeillot (Chief Executive Officer) sold ~$798K of Repligen
Scheduled in advanceTraded Oct 5 · filed 1 day later
Derivative exercise or conversion — not an open-market buy.